Craig-Hallum raised the firm’s price target on Champions Oncology (CSBR) to $8 from $6 and keeps a Buy rating on the shares. The firm notes Champions’ Q2 results were very strong as the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback